Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
Remarkable progress has been made in establishing the field of genomic medicine during the past decade. A host of therapeutic and diagnostic tools—such as the use of molecular simulations to identify new drug pathways1 and gene expression profiles to predict the course of breast cancer2—are moving from the laboratory to the marketplace. Amid the speculation about possible applications and effects of this new medical discipline, 2 major projections have emerged. One predicts that genomic medicine will disrupt many aspects of health care, making current models of its delivery obsolete. Recent reports by the UK National Health Service3 and the US National Human Genome Research Institute4,5 reflect this view. The other is less radical, projecting an initial enhancement of current uses of DNA and genetic information, followed by a gradual diffusion of new genomic medical information and technologies throughout the health care system.6-8
Billings PR, Carlson RJ, Carlson J, et al. Ready for Genomic Medicine? Perspectives of Health Care Decision Makers. Arch Intern Med. 2005;165(16):1917–1919. doi:10.1001/archinte.165.16.1917
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: